SCHEMBL18742873

SCHEMBL18742873

Cc1cc(-c2ccc(CNc3ncnc(N4CCc5c(Br)cccc5C4)c3F)cc2)ccn1

nearest known ligand 0.41

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ WNT3A P56704 16/20 0.41
▸ PDE10A Q9Y233 1/20 0.36
▸ EGFR P00533 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18743502 0.92 WNT3A (0.44) WNT3APDE10A
SCHEMBL18742887 0.89 WNT3A (0.42) WNT3A
SCHEMBL18743498 0.88 GRIN2D (0.45) WNT3A
SCHEMBL18742909 0.86 WNT3A (0.43) WNT3APDE10A
SCHEMBL18742917 0.85 WNT3A (0.48) WNT3APDE10A
SCHEMBL18743501 0.83 WNT3A (0.43) WNT3APDE10AEGFR
SCHEMBL23396776 0.79 WNT3A (0.42) WNT3A
SCHEMBL18742890 0.79 WNT3A (0.43) WNT3APDE10A
SCHEMBL18742880 0.77 WNT3A (0.45) WNT3A
SCHEMBL18703779 0.76 HDAC6 (0.42) WNT3APDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3359154-B1 WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) 2021-05-26 — — EP disclosed
US-20200048223-A1 WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) 2020-02-13 — — US disclosed
US-10450300-B2 Wnt signaling pathway inhibitors and therapeutic applications thereof Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) 2019-10-22 — — US disclosed
WO-2017062688-A1 WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) 2017-04-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10450300-B2 Wnt signaling pathway inhibitors and therapeutic applications thereof WNT1, WNT3A, CTNNB1 WNT3A 2/4885PDE10A 2312/4885EGFR 530/4885
US-20200048223-A1 WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF WNT1, WNT3A, CTNNB1 WNT3A 2/4885PDE10A 2312/4885EGFR 530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback